Therapeutic Update

Mallinckrodt Pharmaceuticals continues to evaluate the totality of clinical evidence for adrabetadex (VTS-270) which includes data from VTS301 Part A/B (our pivotal study), data from the Rush University Medical Center (RUMC) Expanded Access Program (EAP), and data from the VTS301 Part C open-label study which is actively treating patients who participated in the VTS301 Part A/B safety and efficacy study. Additionally, the current EAPs, including the Rush EAP and EAPs in Germany, Australia and various sites in the U.S. are continuing. Lastly, we are working with the NIH to evaluate data from the NIH Natural History Study of NPC so that any insights may appropriately be shared in the future to help advance the understanding of the disease.

Adrabetadex (VTS-270) is an investigational agent. The safety and effectiveness of adrabetadex (VTS-270) has not been established by the FDA or any Regulatory authority.